Kilitch drugs (India) Limited successfully conducted its Extra-Ordinary General Meeting on March 13, 2026, addressing significant corporate restructuring initiatives through video conferencing. Following overwhelming shareholder approval for bonus share issuance, the pharmaceutical company has now announced the record date for determining eligible shareholders.

Record Date and Allotment Timeline

The company has officially fixed March 24, 2026 as the record date for determining shareholders entitled to receive bonus equity shares in the ratio of 1:1. This announcement was made through a regulatory filing to BSE Limited and National Stock Exchange of India Limited under Regulation 42 of SEBI regulations.

Eligibility Criteria for Bonus Shares

Shareholders whose names appear on the company's register of members for physical shares and on the register of beneficial owners maintained by depositories for electronic shares as of closing hours on March 24, 2026 will be entitled to receive the bonus equity shares. The bonus issue offers existing shareholders one additional equity share of ₹10 each for every share held.

EGM Resolutions and Voting Results

The bonus share proposal was approved during the Extra-Ordinary General Meeting held on March 13, 2026, from 11:30 am to 11:42 am through video conferencing. Both major resolutions presented to shareholders received overwhelming support.

Shareholder Participation and Compliance

The EGM witnessed participation from 48 members, including 3 promoter group members and 45 public shareholders. The meeting was chaired by Mr. Mukund Mehta, Managing Director, with comprehensive participation from the leadership team including Mrs. Mira Mehta, Mr. Bhavin Mehta, and three Independent Directors.

The record date announcement, signed by Managing Director Mukund Mehta, ensures full compliance with regulatory requirements and marks the completion of the bonus share issuance process that will strengthen the company's capital structure while rewarding existing shareholders.

Kilitch drugs (India) Limited has announced an Extraordinary General Meeting (EGM) scheduled for Friday, March 13, 2026, at 11:30 AM (IST) through video conferencing. The pharmaceutical company seeks shareholder approval for two significant corporate actions: increasing authorized capital and issuing bonus shares to reward shareholders.

Key Meeting Details

The EGM will be conducted exclusively through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) in compliance with MCA and SEBI circulars. The company has set important dates for shareholder participation:

Authorized Capital Increase Proposal

The first resolution seeks to increase the company's authorized share capital substantially. The proposal involves expanding the capital base to facilitate future fund raising and bonus share issuance:

This increase requires amendment to Clause V of the company's Memorandum of Association and will be passed as an Ordinary Resolution under Sections 13 and 62 of the Companies Act, 2013.

Bonus Share Issue in 1:1 Ratio

The second resolution proposes issuing bonus shares in a 1:1 ratio, meaning shareholders will receive one bonus share for every existing share held. The company plans to capitalize reserves for this distribution:

The bonus issue will be funded from the company's free reserves and securities premium, based on the unaudited balance sheet as of December 31, 2025. This proposal requires approval as a Special Resolution under Section 63 of the Companies Act, 2013.

Voting and Participation Process

Shareholders whose names appear in the Register of Members or Register of Beneficial Owners as on the cut-off date of March 4, 2026, will be eligible to participate in remote e-voting and the EGM. The company has engaged MUFG Intime India Private Limited to provide e-voting services through their InstaVote platform.

Members can access the voting facility through multiple channels including NSDL and CDSL depository websites, or directly through the InstaVote portal for physical shareholders. The company will also provide e-voting facility during the EGM for those who haven't voted remotely.

Corporate Rationale

The management stated that the authorized capital increase will facilitate future fund raising activities and the proposed bonus issue. The company has consistently rewarded shareholders and built substantial free reserves over the years through strong revenue and profit performance. The 1:1 bonus ratio reflects the board's confidence in sharing the company's accumulated reserves with shareholders while maintaining adequate capital for future growth initiatives.